Drug Trial Radar · NCT03178149
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Jan 30, 2019
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Astellas Institute for Regenerative MedicineAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult. ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD. Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD. This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections. There will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317. Different small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year). During all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.
Conditions
- Age-Related Macular Degeneration
Interventions
ASP7317Drug
subretinal injection
tacrolimusDrug
oral
trimethoprim-sulfamethoxazoleDrug
oral
AcyclovirDrug
oral
NystatinDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES)Time frame: Up to 52 Weeks
- Safety as assessed by incidence, frequency and severity of Serious Adverse Events (SAEs)Time frame: Up to 52 Weeks
- Safety assessed by Adverse Events (AEs) of special interestTime frame: Up to 52 Weeks
- Number of participants with cellular graft failure or rejectionTime frame: Up to 52 Weeks
- Incidence of cellular graft failure or rejectionTime frame: Up to 52 Weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Retinal Consultants of Arizona LTD, Retinal Research Institute
Phoenix, Arizona · Withdrawn
Jules Stein Eye Institute
Los Angeles, California · Recruiting
Stanford University Byers Eye Institute
Palo Alto, California · Recruiting
Kaiser Permanente Riverside Medical Center
Riverside, California · Recruiting
Retina Consultants of Southwest Florida & National Ophthalmic Research Institute
Fort Myers, Florida · Withdrawn
Retina Specialty Institute
Pensacola, Florida · Recruiting
Emory University Eye Center
Atlanta, Georgia · Recruiting
University Retina and Macula Associates
Oak Forest, Illinois · Recruiting
Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office
Boston, Massachusetts · Withdrawn
Ophthalmic Consultants of Boston
Boston, Massachusetts · Recruiting
University of Michigan Kellog Eye Center
Ann Arbor, Michigan · Recruiting
Deep Blue Retina
Southaven, Mississippi · Recruiting
NJ Retina
New Brunswick, New Jersey · Withdrawn
Casey Eye Institute Oregon Health & Science University
Portland, Oregon · Recruiting
Mid-Atlantic Retina
Philadelphia, Pennsylvania · Recruiting
Tennessee Retina, PC
Nashville, Tennessee · Withdrawn
Retina Foundation of the Southwest
Dallas, Texas · Recruiting
Valley Retina Institute
McAllen, Texas · Completed
University of Washington
Seattle, Washington · Withdrawn
Spokane Eye Clinical Research
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.